This work relates to the use of aazacitidine (Vidaza, Celgene) as a treatment option for people with myelodysplastic syndromes and certain other related conditions. The NICE Decision Support Unit, based within HEDS, were asked to provide a critical appraisal of the evidence submitted by Celgene and the MDS Foundation in response to NICE’s requests following a partially upheld appeal. A second ACD has now been issued, with the NICE not recommending azacitidine as a treatment option.
For further details contact Sarah Davis.